© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Phenylephrine Related Compound D traces its story back to the evolving landscape of decongestant chemistry. Phenylephrine came into wide use as regulators questioned and tightened controls around pseudoephedrine, which had fallen out of favor for safety and abuse-related reasons. In this shuffle, attention turned toward related compounds, each with distinct properties influencing drug stability, bioavailability, and purity. Compound D entered the conversation as chemists dug deeper into the nitty-gritty of phenylephrine’s synthetic pathways. Regulatory guidelines, especially those about impurity profiles in pharmaceuticals, fueled a drive to map out, quantify, and control the presence of Related Compound D, illuminating both its chemical character and practical importance beyond obscure academic circles.
At the core, Compound D emerges not as a mystery ingredient, but as a normal byproduct in phenylephrine’s chemical synthesis. Its structure rings familiar to anyone with a background in organic chemistry: a backbone resembling that of phenylephrine, but tweaked at key positions. These small twists mean the compound plays a different tune in both biological and quality control contexts. Labs around the world have wrestled with the challenge of identifying and quantifying Compound D as new analytical techniques—think high-performance liquid chromatography and mass spectrometry—pushed sensitivity and selectivity to new heights. The process still involves hunting shadows to guarantee that medications lining pharmacy shelves deliver what labels promise, free from surprise extras.
Anyone who’s seen Compound D under a microscope, or at the bench, notices clear physical cues: typically a solid, with characteristics like melting point, solubility, and crystalline habits all distinct from its parent compound. These properties influence how easily it separates out during purification, how it interacts with other components in drug formulations, and whether it lingers in finished products. In the world of chemistry, even the subtlest difference in solubility or melting behavior can determine whether a trace byproduct sticks around or washes away—something regulators and industry watchdog groups pay close attention to. Chemically, the functional groups that set Compound D apart mean it dances to its own tune during reactions, creating both opportunities and headaches for those refining synthesis steps.
Regulatory pressures shape how companies label and test for Compound D in finished products. Pharmacopoeias and drug monographs keep expanding impurity guidelines, forcing manufacturers to keep levels of Related Compound D in check, quantified down to tenths or hundredths of a percent. The accuracy of these measurements holds enormous weight. During FDA or EMA inspections, failing to prove rigorous control of impurities—especially for compounds like D with known or unknown risks—can hold up product approvals or trigger recalls. Each updated guideline means a lab somewhere scrambles to refine protocols, invest in calibration standards, and run endless validation studies. This sheer amount of lab work shows just how much investment compliance demands, both in time and scientific brainpower.
Preparation of Compound D often stems from the main path used to make phenylephrine, either as a minor side reaction or through degradation. Steric hindrance, temperature controls, pH levels, and reagent purity all play a part in how much of D appears in a given batch. Some labs have studied alternative routes that yield higher amounts for research, by leveraging conditions that favor its specific structural formation. Once isolated, Compound D behaves predictably in classic reactions—forming salts, reacting with acids or bases, and giving telltale signals on spectroscopy. Every bit of this chemical detective work shines a light on how deliberate or accidental changes in process conditions can tip the balance between purity and impurity.
Tracking down Compound D across literature and regulatory texts throws up a real challenge. It appears under various synonyms, with each pharmacopoeia or lab favoring shorthand or systematic names that sometimes muddy the waters. Without a firm grip on these aliases, researchers risk missing key safety signals or process improvements outlined by others. This lack of unified naming also leads to confusion in global markets, slowing regulatory approvals across borders and creating extra hurdles for multinational pharmaceutical companies that navigate an ocean of paperwork in multiple languages and standards.
Labs and manufacturing sites dealing with Related Compound D face tight operational safeguards. Gloveboxes, well-ventilated fume hoods, and standardized clean-up procedures take top priority, minimizing exposure risk. Training staff isn’t treated as a box-ticking exercise; it becomes the frontline against cross-contamination or accidental release. Regular equipment validation and system checks aim to flag deviations from procedure before minor problems transform into major recalls. In personal experience, strong safety culture grows from constant drills, sharing near-miss lessons, and respecting that ‘trace’ compounds can cause big problems if ignored.
While Compound D doesn’t headline as an active pharmaceutical ingredient, its presence as an impurity shapes the industry’s approach to product safety and consistency. Finished drug formulations—tablets, syrups, and more—undergo rigorous quality control to ensure that Compound D never exceeds prescribed thresholds. The rules are especially strict for products used by children, the elderly, or patients with specific health risks. Even small-scale custom formulations, such as hospital-pharmacy mixtures, take cues from the work done on industrial production lines. Over the years, the chase for lower impurity levels has sharpened the tools labs use for everything from compounding to packaging.
University groups and R&D labs give Compound D more attention than the public realizes. Papers track its formation, breakdown, and impact on drug stability over time. Some teams use it to refine analytical methods, since tracking an elusive impurity sharpens their ability to spot new or unexpected compounds down the line. Others test its chemical behavior for possible uses in synthetic chemistry, though most findings keep it confined to the context of impurity control. These efforts reflect a broader move to dissect the full impurity spectrum for every medicine cleared for sale, catching rare or slow-forming compounds before they reach the marketplace.
Toxicology sits front and center whenever a new or newly-noticed compound surfaces. For Compound D, researchers have examined its behavior in animal models, cell cultures, and chemical simulations to check for risks like mutagenicity or cumulative toxicity. So far, public reports haven’t linked it to broad health crises, though regulators insist on keeping exposures well below any level that might set off alarms. Toxicity screens run side by side with environmental impact studies, making sure trace amounts flushed or discarded don’t cause problems downstream. Even without red flags, risk management keeps driving further study, especially as more sensitive detection methods find the compound in unexpected places.
Looking forward, the focus is likely to sharpen on deeper impurity profiling and even stricter control thresholds. Research dollars flow into faster, more sensitive testing, pushing detection limits lower every year. Data sharing—both between companies and across borders—could speed up early warning for new or previously underrated risks. Some believe new synthesis routes will eventually all but eliminate Related Compound D, but the chemical realities make zero-tolerance a moving target. As consumer awareness grows, and with regulatory “all clear” standards rising, the pharmaceutical world keeps building its playbook for handling both headline and so-called ‘background’ compounds. The lesson here is that no detail, however minor, escapes scrutiny for long in modern medicine.
Walk through the cold and flu aisle, and phenylephrine pops up on more labels than people expect. It's one of those active ingredients that many folks trust to clear up stuffy noses and help with sinus pressure. For decades, doctors and pharmacists have handed out or suggested medicines with this compound, banking on both science and real-world experience. Behind every familiar over-the-counter tablet, there's a whole hidden world, including chemical byproducts called "related compounds."
No lab process gives you a perfect result—even with strict controls, small side-products form along the way. Scientists call these “related compounds.” They monitor these traces carefully, because sometimes they creep into the final product in tiny amounts. Phenylephrine Related Compound D falls in this group; it’s not the main character, but it’s always around when making or storing phenylephrine. Chromatography and other lab tests often pick up these small extras, even if consumers never see them on a label.
Trust in medicine rides on what’s truly in each dose. Any related compound, including Compound D, signals how pure or stable a medicinal ingredient stays after it’s made, shipped, and stored on the shelf. Health authorities like the FDA and regulators around the world pay close attention, studying how much of these compounds show up and if they could harm patients. A harmless related compound might not change anything for someone with a cold. Others—especially if they gather at higher-than-expected levels—spark deeper concern because they could affect safety or change how well the medicine works. This tension keeps drug makers on their toes.
Heat, humidity, or the presence of light can nudge medicines to change. Phenylephrine doesn’t escape this rule. Over time or through certain production quirks, Compound D can show up in measurable amounts. That’s why chemists at manufacturing plants run their analyses with rigorous frequency. They tweak production steps or use special packaging to keep related compounds—especially Compound D—at bay. Revising a process may cost more and stretch deadlines, but the price of overlooking these details shows up in product recalls and worried headlines.
Health systems learned lessons from past scares—earlier, nobody gave much thought to what sat in tablets besides the intended active ingredient. Now, guidelines demand strict monitoring of all related compounds, some of which are specifically named and tracked batch by batch. Knowing what Compound D does, and what risks it brings (if any), lets both the drug maker and the consumer breathe easier. Some companies invest in research to break down how these byproducts form, share data with regulators, or design “cleaner” processes that sidestep unwanted chemistry altogether. Researchers use these findings to update standards, striking a balance between offering safe, reliable relief and keeping production costs grounded.
In my days working the pharmacy counter, questions about “impurities” came up more than people might think. Folks wanted to know if anything else made its way into their pill bottles besides what the front of the box promised. Transparency builds trust, plain and simple. Explaining what these related compounds are, how they are tracked and kept in line, often helped calm fears. It’s not about sweeping side-products away—it's about showing that science is working for the person reaching for relief.
Chemistry classes in college taught me that each molecule has its own story. Phenylephrine is a household name in the medicine cabinet, showing up in cold remedies everywhere, but hidden behind the main ingredient, you'll find a few “related compounds” that keep researchers and pharmacists on their toes. Phenylephrine Related Compound D grabs attention for a good reason: its structure can impact both the drug’s purity and what patients experience.
If you look at the chemical skeleton, Phenylephrine itself comes with a benzene ring, a two-carbon chain, and a hydroxyl group. It’s an alpha-adrenergic agonist—meaning it affects how blood vessels contract. Compound D doesn’t stray far from this backbone. The most common form is known as meta-hydroxyphenylephrine or 3-hydroxyphenylephrine. Both names point to the same chemical: 3-Hydroxy-α-[(methylamino)methyl]benzyl alcohol. This structure looks similar to phenylephrine, but the position of a hydroxyl group slides over to the meta spot on the benzene ring. The change might feel subtle, but it often marks the difference between a helpful medicine and a possible impurity question mark.
I remember working with a colleague in a quality control lab, running HPLC tests to detect trace amounts of related compounds in a pharmaceutical batch. Even a small amount of impurity—like Compound D—sets off alarms. In medications, safety and consistency matter more than profit margins or speed. According to FDA guidance, impurities above specific thresholds must be identified, and their safety evaluated. The wrong structural cousin in the mix can lead to allergic reactions or changes in how effective a drug turns out to be. Phenylephrine’s effectiveness itself has been questioned in recent years, but its related impurities must still be kept in check to meet global pharmacopoeia standards.
The structure of Compound D means chemists can track it using UV detection or mass spectrometry. Laboratories use reference materials with the exact same structural fingerprint to compare and verify that finished products don’t exceed allowable levels of this compound. That’s a big chunk of the trust we place in over-the-counter medicines: somebody has checked what’s inside, down to the molecule.
Keeping Phenylephrine Related Compound D under control takes vigilance. Some manufacturers invest in better purification systems, tailoring their crystallization or distillation steps to weed out closely related molecules. Investing in accurate analytical chemistry tools also pays off. I’ve seen how updating lab methods—switching from old colorimetric tests to modern chromatography—catches impurities long before tablets reach the shelf.
Building a culture of quality isn’t just about catching problems; it’s about making sure those problems never arise. Continuous training for lab staff, tighter supplier controls, and open reporting help reduce contamination risks. As regulatory bodies raise questions about both the main drug and its side products, evidence-based decision making will shape which compounds stick around in our medicine and which ones need to be limited or eliminated.
Patients trust medicines to be what their labels claim, and that trust comes down to knowledge of every compound present. Taking Phenylephrine Related Compound D seriously, from structural understanding to strict lab monitoring, helps protect not just supply chains but the health of people who count on these medicines every cold and flu season.
Walking into any pharmacy, most people never question how their medicines stay safe. Hidden behind those brightly colored packages, a lot of chemistry checks and balances keep everything in line. Phenylephrine, a popular nasal decongestant, passes through a gauntlet of tests before reaching the shelf. Along that path, related compounds—like Phenylephrine Related Compound D—matter more than you might guess.
Researchers keep their eyes peeled for these related compounds during quality control. The U.S. Pharmacopeia sets the rules, and pharmaceutical labs follow with good reason. Every batch of phenylephrine comes with trace chemicals that form during synthesis or break down over time. Compound D stands out as one of the key markers.
Why track it? Even tiny amounts can tip the balance from safe to concerning. Regulations demand that companies measure and control related compounds to avoid health risks. Technicians identify and quantify Compound D using high-performance liquid chromatography (HPLC). This tool acts like a molecular colander: separating, measuring, and flagging anything that doesn’t belong. If levels of Compound D cross a set threshold, the whole batch gets rejected.
The presence of Related Compound D signals that manufacturing hit a bump. No process turns out 100% pure phenylephrine; there’s always a little leftover from the chemical process. Exposing patients, especially those with fragile health, to unknown quantities of byproducts simply isn’t smart. No one’s interested in surprise side effects, and oversight grows tighter by the year.
Recalls and regulatory hits cost time and reputation. By nailing down methods to measure Compound D accurately, companies can focus on safety from the start. I remember a particularly tense month working in a quality control lab, where one spike in an impurity sent dozens of employees back to their notepads, stripping down the process step-by-step. Public trust rode on getting it right.
Strict documentation backs up every decision. Reports go straight to regulatory bodies, full of HPLC graphs and hard numbers. Inspectors review these records without mercy. If an impurity, like Compound D, isn’t reported accurately or stays above limits, warnings, fines, or shutdowns can follow.
Consistent protocols cut down on risks. Method validation—testing and retesting lab approaches—separates solid companies from the rest. This isn’t just technical showboating; it saves lives. One bad pill can set off a legal and ethical storm. Knowing exactly what’s inside, down to the smallest compound, gives patients and professionals real peace of mind.
Labs keep searching for fresher, sharper detection methods. Advances in analytical chemistry, such as ultra-high-performance liquid chromatography or mass spectrometry, let scientists see the world at an atomic scale. Faster, clearer results help public health and business. Investing in better analysis tools means products get safer every year. Watching teams hustle in the lab, the message comes through: keeping impurities like Phenylephrine Related Compound D in check isn’t just science—it’s responsibility.
Anyone working in a pharmacy or laboratory comes across tough storage decisions every day, and Phenylephrine Related Compound D fits squarely into that routine. This stuff demands respect on the shelf, not because it’s fancy, but because a lot goes wrong if you get lazy about its conditions. Honestly, I’ve seen entire batches go south from careless storage, and there’s not enough coffee to fix that headache.
Most folks in the know keep Phenylephrine Related Compound D stashed at room temperature—think somewhere between 20°C and 25°C. Fluctuations can do more than just make the labeling curl; they can push chemical breakdown to a new level. Even if a few degrees off feels trivial, temperature swings spark reactions that nobody needs in their quality reports. I’ve found temperature data loggers to be a solid investment. They catch issues before they become problems, and you sleep better at night.
This compound turns a bit skittish around light. Direct sunlight can kick off degradation, eventually leaving you with a product less reliable than a faulty printer. Simple amber bottles or aluminum foil can work wonders. In places with big windows or open shelving, it makes sense to store the compound in drawers or cabinets.
No one has time for the frustration that comes from contamination by humidity. Water in the air can make powders clump and shift the chemistry in weird ways, often without clear warning. The trick here is airtight containers with desiccant packets. I remember trying to cut corners with basic seal caps—every time, I ended up with wasted compound and extra paperwork. Dry, tight storage pays you back in uninterrupted workflow and steady potency.
Labels might seem tedious, but clarity saves skin in audit season. With Phenylephrine Related Compound D, even something minor like a smudged date or unclear initials adds confusion. Stick to permanent ink, cover up labels with transparent tape, and log every movement or use. In the labs where tracking slips, accountability goes with it, and quality takes a tumble.
Published data backs up these working habits. The U.S. Pharmacopeia spells out conditions for many active pharmaceutical ingredients and related compounds, including recommendations for temperature and humidity. Researchers at institutions like the American Chemical Society stress that small chemical changes can pile up, and the difference between “potent” and “degraded” usually starts in storage. This isn’t overkill; it’s just how molecular stability works. The stakes might be different if you’re in research versus manufacturing, but cutting corners invites trouble either way.
No technician, pharmacist, or scientist manages storage in a vacuum. Training the whole crew builds a habit of vigilance. Unannounced checks, quick refreshers, and shared responsibility turn storage from a chore into a point of pride. In every lab I’ve worked, the teams that took these little details seriously ran into fewer product recalls, less confusion, and a smoother ride come inspection time.
Smart storage for Phenylephrine Related Compound D boils down to doing the basics well. Paying attention to temperature, light, and moisture puts you way ahead of the game, and brings the lab a lot less chaos down the line.
Trusting the label means trusting the supply chain. In pharmaceuticals and related compounds, buyers rely heavily on the accuracy of what’s shipped to their door. For phenylephrine related compound D, a certificate of analysis—or COA—acts like a verified promise that the substance really matches what the seller claims. Without a COA, you’re flying blind, exposing yourself to more risk than most professionals are willing to accept.
Phenylephrine related compound D, as a pharmaceutical impurity or as a reference standard, often gets used for research or regulatory purposes. A batch without a clear history becomes a mystery: unknown purity, unverified identity, uncertain stability. These aren’t small issues. For labs tasked with drug testing or regulatory compliance, skipping a COA can invite regulatory and financial penalties. The FDA and other agencies insist on COAs because too many cases have shown that lax standards cause harm. Mixing up compounds, or missing unlisted contaminants, can literally put patients at risk.
A proper COA doesn’t just list the chemical’s name. It includes exact methods used to check purity, detailed results from those tests, known impurities, storage recommendations, and the date it left the manufacturer’s hands. It’s about traceability—a direct line back to the lab that performed the tests, plus contact information, batch numbers, and signatures. No one wants to chase faceless companies or ambiguous certificates if regulators ever knock on the door.
Most established chemical suppliers recognize that advanced buyers won’t order phenylephrine related compound D (or any reference impurity) without a COA, because regulatory agencies scrutinize everything from analytical standards to final formulations. Some smaller vendors try to skip this paperwork, or issue generic, non-specific “certificates” that lack real data. That’s a red flag. If the paperwork feels vague, if numbers are missing, or if you see one-word purity claims without explanation, the supplier probably cuts corners elsewhere too.
The supply chain for analytical standards keeps getting more global and more complicated. In recent years, import crackdowns and tighter customs screenings have exposed counterfeit standards and incomplete certificates as a recurring problem—not just rarities. This reality means buyers have to dig a little deeper. Ask vendors direct questions about the origin of phenylephrine related compound D: which lab ran the analysis, what techniques they used, how recently it was tested. A responsible supplier answers directly and backs it up with documents.
Transparency solves most of the headaches. Professional labs and research facilities tend to stick to reputable distributors, because every missing detail could trip up a whole project or cause an audit issue later. The pressure isn’t just coming from regulators, either. End-users and auditors place more value on documentation and clear provenance than ever before. Digital COAs, with QR codes that pull up original lab data, lead the way. Some companies have made it normal to publicize testing methods and staff credentials to reaffirm trust, sidestepping the shadows that let low-quality or fake standards slip through.
As the industry continues to increase transparency, the real winners are those who demand proof at every step—real data, real signatures, real accountability. Buying phenylephrine related compound D with a COA isn’t just regulatory box-ticking. It’s the foundation of safe research, clear results, and better outcomes for everyone downstream.
| Names | |
| Preferred IUPAC name | 3-(1,2-Dimethylphenoxy)-1-phenylpropan-2-ol |
| Other names |
4-Hydroxyphenylephrine |
| Pronunciation | /fɛˌnaɪlˈɛfrɪn rɪˈleɪtɪd ˈkɒmpaʊnd diː/ |
| Identifiers | |
| CAS Number | 21898-19-1 |
| Beilstein Reference | 1209227 |
| ChEBI | CHEBI:8093 |
| ChEMBL | CHEMBL3331050 |
| ChemSpider | 10285416 |
| DrugBank | DB09236 |
| ECHA InfoCard | ECHA InfoCard: 100.031.417 |
| EC Number | EC 231-818-8 |
| Gmelin Reference | 8776 |
| KEGG | C15694 |
| MeSH | D007561 |
| PubChem CID | 122129 |
| RTECS number | DN3150000 |
| UNII | 009PO3F8YK |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID50871398 |
| Properties | |
| Chemical formula | C9H13NO2 |
| Molar mass | 321.82 |
| Appearance | White to off-white solid |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | -0.52 |
| Acidity (pKa) | 9.4 |
| Basicity (pKb) | 8.92 |
| Dipole moment | 3.11 D |
| Thermochemistry | |
| Std enthalpy of combustion (ΔcH⦵298) | -5732.7 kJ/mol |
| Pharmacology | |
| ATC code | R01BA03 |
| Hazards | |
| Main hazards | Causes serious eye damage. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. |
| NFPA 704 (fire diamond) | 1-2-0 |
| NIOSH | WI980CZE4R |
| REL (Recommended) | 0.5% |
| Related compounds | |
| Related compounds |
Phenylephrine Phenylephrine Related Compound A Phenylephrine Related Compound B Phenylephrine Related Compound C Phenylephrine Related Compound E |
